PAY WITH BITCOIN $ GET 10% OFF
Facebook Twitter Email Pinterest linkedin
  • NEWSLETTER
  • CONTACT US
  • FAQs

Phone:+1 (415) 598 7396

Email:[email protected]

Call toll-free

+1 (415) 598 7396

Any questions

[email protected]

Oxford City Online Pharmacy
Login / Register
0 items / $0
Oxford City Online Pharmacy
  • Home
  • Pills
    • BENZOS AND PAINKILLERS
    • SEX PILLS
    • POWDER
  • STEROID
    • ORAL STEROID
    • INJECTABLE STEROID
  • HUMAN GROWTH HORMONES(HGH)
  • PEPTIDES
  • About Us
  • Contact Us
  • SHIPPING POLICY
  • RETURN POLICY
  • Track order
Menu
Login / Register

Sign inCreate an Account

Lost your password?
0 items / $0
Click to enlarge
HomeSTEROIDORAL STEROID Novladex Tamoxifen Citrate 10 Mg
Previous product
Naposim Methandienone 5mg $20
Back to products
Next product
Oxymetholone 50mg $50

Novladex Tamoxifen Citrate 10 Mg

$20

NOLVADEX (tamoxifen citrate) is a nonsteroidal agent that has demonstrated potent antiestrogenic properties in animal test systems. The antiestrogenic effects may be related to its ability to compete with estrogen for binding sites in target tissues such as breast.

Category: ORAL STEROID
Share
Facebook Twitter Email Pinterest linkedin
  • Description
  • Reviews (0)
Description

what is Novladex Tamoxifen Citrate 10 mg?

Novladex Tamoxifen Citrate 10 mg is a nonsteroidal agent that has demonstrated potent antiestrogenic properties in animal test systems. The antiestrogenic effects may be related to its ability to compete with estrogen for binding sites in target tissues such as breast. Tamoxifen inhibits the induction of rat mammary carcinoma induced by dimethylbenzanthracene (DMBA) and causes the regression of already established DMBA-induced tumors. In this rat model, tamoxifen appears to exert its antitumor effects by binding the estrogen receptors.

In cytosols derived from human breast adenocarcinomas, tamoxifen competes with estradiol for estrogen receptor protein.

Absorption and Distribution of Novladex Tamoxifen Citrate 10 mg

Following a single oral dose of Novladex Tamoxifen Citrate 10 mg, an average peak plasma concentration of 40 ng/mL (range 35 to 45 ng/mL) occurred approximately 5 hours after dosing. The decline in plasma concentrations of tamoxifen is biphasic with a terminal elimination half-life of about 5 to 7 days. The average peak plasma concentration of N-desmethyl tamoxifen is 15 ng/mL (range 10 to 20 ng/mL). Chronic administration of 10 mg tamoxifen given twice daily for 3 months to patients results in average steady-state plasma concentrations of 120 ng/mL (range 67-183 ng/mL) for tamoxifen and 336 ng/mL (range 148-654 ng/mL) for N-desmethyl tamoxifen. The average steady-state plasma concentrations of tamoxifen and N-desmethyl tamoxifen after administration of 20 mg tamoxifen once daily for 3 months are 122 ng/mL (range 71-183 ng/mL) and 353 ng/mL (range 152-706 ng/mL), respectively. After initiation of therapy, steady state concentrations for tamoxifen are achieved in about 4 weeks and steady-state concentrations for N-desmethyl tamoxifen are achieved in about 8 weeks, suggesting a half-life of approximately 14 days for this metabolite. In a steady-state, crossover study of 10 mg NOLVADEX (tamoxifen citrate) tablets given twice a day vs. a 20 mg NOLVADEX (tamoxifen citrate) tablet given once daily, the 20 mg NOLVADEX (tamoxifen citrate) tablet was bioequivalent to the 10 mg NOLVADEX (tamoxifen citrate) tablets.

Metabolism

Tamoxifen is extensively metabolized after oral administration. N-desmethyl tamoxifen is the major metabolite found in patients’ plasma. The biological activity of N-desmethyl tamoxifen appears to be similar to that of tamoxifen. 4-Hydroxytamoxifen and a side chain primary alcohol derivative of tamoxifen have been identified as minor metabolites in plasma. Tamoxifen is a substrate of cytochrome P-450 3A, 2C9 and 2D6, and an inhibitor of P-glycoprotein.

Excretion

Studies in women receiving 20 mg of 14C tamoxifen have shown that approximately 65% of the administered dose was excreted from the body over a period of 2 weeks with fecal excretion as the primary route of elimination. The drug is excreted mainly as polar conjugates, with unchanged drug and unconjugated metabolites accounting for less than 30% of the total fecal radioactivity.

Special Populations

The effects of age, gender and race on the pharmacokinetics of tamoxifen have not been determined. The effects of reduced liver function on the metabolism and pharmacokinetics of tamoxifen have not been determined.

Pediatric Patients

The pharmacokinetics of Novladex Tamoxifen Citrate 10 mg and N-desmethyl tamoxifen were characterized using a population pharmacokinetic analysis with sparse samples per patient obtained from 27 female pediatric patients aged 2 to 10 years enrolled in a study designed to evaluate the safety, efficacy, and pharmacokinetics of NOLVADEX (tamoxifen citrate) in treating McCune-Albright Syndrome. Rich data from two tamoxifen citrate pharmacokinetic trials in which 59 postmenopausal women with breast cancer completed the studies were included in the analysis to determine the structural pharmacokinetic model for tamoxifen. A one-compartment model provided the best fit to the data.

In pediatric patients, an average steady state peak plasma concentration (Css, max) and AUC were of 187 ng/mL and 4110 ng hr/mL, respectively, and Css, max occurred approximately 8 hours after dosing. Clearance (CL/F) as body weight adjusted in female pediatric patients was approximately 2.3-fold higher than in female breast cancer patients. In the youngest cohort of female pediatric patients (2-6 year olds), CL/F was 2.6-fold higher; in the oldest cohort (7-10.9 year olds) CL/F was approximately 1.9-fold higher. Exposure to N-desmethyl tamoxifen was comparable between the pediatric and adult patients. The safety and efficacy of Novladex Tamoxifen Citrate 10 mg for girls aged two to 10 years with McCune-Albright Syndrome and precocious puberty have not been studied beyond one year of treatment. The long-term effects of Novladex Tamoxifen Citrate 10 mg therapy in girls have not been established. In adults treated with Novladex Tamoxifen Citrate 10 mg an increase in incidence of uterine malignancies, stroke and pulmonary embolism has been noted

Reviews (0)

Reviews

There are no reviews yet.

Be the first to review “Novladex Tamoxifen Citrate 10 Mg” Cancel reply

Your email address will not be published. Required fields are marked *

Related products

Close

Proviron Schering 25 Mg

$20
Add to cart
Close

Himalaya Liv52 Detox 375 Mg

$30
Add to cart
Close

D-Bol Methandienone 10mg 100tabs

$35
Add to cart
Close

D-Bol Methandienone 5mg 1000 Tabs

$110
Add to cart
Close

1mg Anastrozole 100 Tabs

$40
Add to cart
Close

Turinabol 10mg

$30
Add to cart
Close

Halotest Fluoxymesterone 10mg 25tabs

$35
Add to cart
Close

Himalaya LIV 52 DS TABLETS 60tabs

$25
Add to cart
© 2020 Oxford City Pharmacy Inc. All Rights Reserved.

Shopping cart

close
close
Start typing to see products you are looking for.
Open chat
Powered by
  • Home
  • Pills
    • BENZOS AND PAINKILLERS
    • SEX PILLS
    • POWDER
  • STEROID
    • ORAL STEROID
    • INJECTABLE STEROID
  • HUMAN GROWTH HORMONES(HGH)
  • PEPTIDES
  • About Us
  • Contact Us
  • SHIPPING POLICY
  • RETURN POLICY
  • Track order
  • Login / Register
Scroll To Top